Aquestive Therapeutics, Inc. (AQST) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-06-24

Aquestive Therapeutics, Inc. (AQST) has filed 18 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-06-24. 2 Form 8-K material event filings were reported by AQST in the last 90 days. 4 Form 144 notices of proposed sale were filed for AQST stock. InsiderAlpha tracks every AQST SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Aquestive Therapeutics, Inc. (AQST)

SIC classification	Pharmaceutical Preparations (SIC 2834)
SEC CIK	0001398733

90-Day SEC Filing Activity

Form 4 filings (90d)	18
Form 8-K filings (90d)	2
Form 144 notices (90d)	4
Latest Form 4 filing	2026-06-24

Recent AQST Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-06-23	Krop Julie	Insider	S — Open-market sale	25.0K	$5.02	$125K	SEC
2026-06-23	Krop Julie	Insider	M — Option exercise	25.0K	$0.71	$18K	SEC
2026-06-15	Barber Daniel	President and CEO	S — Open-market sale	25.0K	$4.16	$104K	SEC
2026-06-08	Korczynski Sherry	Chief Commercial Officer	F — Tax withholding / forfeiture	2.7K	$0.00	—	SEC
2026-05-18	Zalewski Thomas A.	Chief Legal Officer	A — Grant or award	100.0K	$0.00	—	SEC
2026-05-15	Cioffi Melina	SVP, Regulatory Affairs	F — Tax withholding / forfeiture	1.7K	$4.17	$7K	SEC
2026-05-15	Barber Daniel	President and CEO	S — Open-market sale	8.3K	$4.29	$35K	SEC
2026-05-07	BRAENDER LORI J	Corporate Secretary	F — Tax withholding / forfeiture	135.7K	$4.23	$574K	SEC
2026-05-05	BRAENDER LORI J	Corporate Secretary	F — Tax withholding / forfeiture	76.1K	$4.18	$318K	SEC
2026-05-05	Barber Daniel	President and CEO	F — Tax withholding / forfeiture	335.9K	$4.18	$1.40M	SEC
2026-05-05	TOTH A ERNEST JR	Chief Financial Officer	F — Tax withholding / forfeiture	92.7K	$4.18	$387K	SEC
2026-05-05	Jung Cassie	Chief Operating Officer	F — Tax withholding / forfeiture	72.7K	$4.18	$304K	SEC
2026-05-05	Boyd Peter E.	Chief People Officer	F — Tax withholding / forfeiture	56.8K	$4.18	$237K	SEC
2026-03-10	TOTH A ERNEST JR	Chief Financial Officer	S — Open-market sale	58.3K	$4.17	$243K	SEC
2026-03-10	BRAENDER LORI J	Chief Legal Officer	S — Open-market sale	40.1K	$4.17	$167K	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Aquestive Therapeutics, Inc. (AQST). Updated in real time as new filings are submitted to the SEC.

Most-Active AQST Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Krop Julie	4	$143K
Barber Daniel	3	$1.54M
Zalewski Thomas A.	2	—
BRAENDER LORI J	2	$892K
Korczynski Sherry	1	—

Recent AQST Form 8-K Material Events

2026-06-10 — Item 5.07, 9.01 [SEC]
2026-05-13 — Item 1.01, 1.02, 2.02, 2.03, 3.02, 7.01, 9.01 [SEC]
2026-03-30 — Item 7.01, 9.01 · Clinical · positive [SEC]
Aquestive Therapeutics announced successful completion of a Type A meeting with the FDA regarding the resubmission of its NDA for Anaphylm (dibutepinephrine) sublingual film for anaphylaxis treatment. The company received preliminary FDA comments, representing progress toward pot
2026-03-20 — Item 5.02, 7.01, 9.01 · Leadership · negative [SEC]
Lori J. Braender, Chief Legal Officer and Chief Compliance Officer of Aquestive Therapeutics, is stepping down from her executive roles effective April 2, 2026, though she will remain employed through May 7, 2026 providing transition services and will continue as Corporate Secret
2026-03-04 — Item 1.01, 2.02, 3.02, 7.01, 9.01 · Financing · mixed [SEC]
Aquestive Therapeutics extended a product milestone deadline with RTW Investments to June 30, 2027, issued a warrant for 375,000 shares at $4.00/share, and secured a $5 million equity commitment from RTW-affiliated funds over 90 days. The company also reported Q4 2025 and full-ye

Recent AQST Form 144 Notices of Proposed Sale

2026-07-15 — — [SEC]
2026-06-23 — — [SEC]
2026-06-15 — — [SEC]

Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.

Recent Insider Filings

2026-06-24 — Krop Julie (Insider)
2026-06-16 — Barber Daniel (President and CEO)
2026-06-12 — MORRIS TIMOTHY E (Insider)
2026-06-12 — Krop Julie (Insider)
2026-06-12 — Jenkins Abigail L. (Insider)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in AQST insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

AQST Insider Trading — FAQ

What is the latest insider trade for AQST?: Aquestive Therapeutics, Inc. (AQST) had 18 insider filings in the last 90 days, with the most recent on 2026-06-24. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying AQST stock?: 0 insider purchases of AQST were filed in the last 90 days.
How many insiders are selling AQST stock?: 0 insider sales of AQST were filed in the last 90 days.
Where can I see AQST SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every AQST SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Related Companies — Recent Insider Activity

Learn More

Open the live AQST dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.